Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Tasly Pharmaceutical Group Co: Clinical Trials & FDA Approval Profile

Tasly Pharmaceutical Group Co (Global / Institutional) sponsors 27 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 13 active protocols (8 recruiting now), 12 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)233 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Tasly Pharmaceutical Group Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)27
Active Pipeline (Recruiting Now)13 (8)
Completed vs Stopped Early12 / 0 (0.0%)
Median Closed Actual Enrollment233 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Tasly Pharmaceutical Group Co
Hospital Research SiteLocationShared Protocols
Beijing HospitalBeijing, Beijing Municipality4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Tasly Pharmaceutical Group Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07687186Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUrePhase IIIRECRUITING
NCT06685978Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary GlandsPhase IIIRECRUITING
NCT04983043Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart FailurePhase IICOMPLETED
NCT04944706Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection FractionPhase IICOMPLETED
NCT06068465A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease PsychosisPhase IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Tasly Pharmaceutical Group Co Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI